Harter, P., Bogner, G., Chiva, L., Cibula, D., Concin, N., Fotopoulou, C., . . . Vergote, I. (2024). Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer. Bulletin du cancer, 111(3), . https://doi.org/10.1016/j.bulcan.2023.02.011
Chicago-Zitierstil (17. Ausg.)Harter, Philipp, et al. "Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Epithelial Ovarian Cancer." Bulletin Du Cancer 111, no. 3 (2024). https://doi.org/10.1016/j.bulcan.2023.02.011.
MLA-Zitierstil (9. Ausg.)Harter, Philipp, et al. "Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Epithelial Ovarian Cancer." Bulletin Du Cancer, vol. 111, no. 3, 2024, https://doi.org/10.1016/j.bulcan.2023.02.011.